AstraZeneca presents Phase 2b VISTA data for elecoglipron: 11.8% weight loss at 36 weeks in obesity

AstraZeneca/Elecoglipron

AstraZeneca presented Phase 2b VISTA trial results showing elecoglipron (AZD5004), an oral GLP-1 receptor agonist, achieved 11.8% weight loss at 36 weeks versus 0.3% with placebo in 310 adults with obesity or overweight. The company is advancing the compound into a Phase 3 program including cardiovascular and kidney outcome trials.